Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Seagen
Biotech
Pfizer’s first new ADC from Seagen buy fails ph. 3 NSCLC trial
The potential first-in-class ADC failed to significantly improve overall survival compared with docetaxel in previously treated nonsquamous NSCLC.
Angus Liu
Jun 23, 2026 7:15am
Pfizer drops another early cancer candidate from Seagen
Mar 19, 2026 12:56pm
Pfizer pulls the plug on 11 programs
Nov 4, 2025 2:40pm
Pfizer taps ex-Novartis leader to helm cancer R&D work
Feb 6, 2025 10:45am
Pfizer axes B7-H4 ADC, triggering $1B impairment charge
Feb 4, 2025 8:46am
Biogen boosts C-suite with BMS vet—Chutes & Ladders
Nov 1, 2024 8:30am
